Ep. 261, Chapter 7: Epic Bio's Strategic Priorities and Capabilities With Amber Salzman, Ph.D.

28:24 – End

Salzman confirms Epic Bio’s epigenetic editing therapy can safely perform multiplexing, meaning a single construct can be designed to make more than one genetic change, such as upregulating one gene while downregulating another. This approach is considered safer than traditional gene-cutting methods, although delivering the therapy to different cell types within the body presents a logistical challenge.

For the second half of 2025, Epic Bio's top priority is advancing its clinical trial for FSHD patients, followed by progressing its other pipeline indications. The company is actively screening and will soon be dosing patients with its lead candidate, EPI-321. Salzman acknowledges that the cost of goods is a consideration for all therapies but believes Epic Bio is well-positioned, particularly given the recent investments in the FSHD space.